<DOC>
	<DOCNO>NCT02533115</DOCNO>
	<brief_summary>This study Phase IV Expanded Access Protocol ( EAP ) CPX-351 patient secondary acute myeloid leukemia suitable treatment intensive chemotherapy .</brief_summary>
	<brief_title>EAP CPX-351 ( VYXEOS ) Patients 60-75 Years Age With Secondary AML</brief_title>
	<detailed_description>The hypothesis CPX-351 treatment may safe efficacious patient newly diagnose secondary AML come single randomized Phase II study observe significant improvement survival 52-patient subset patient secondary AML . A Phase III confirmatory study recently complete accrual final result expect mid-2016 . Therefore , sponsor chosen make CPX-351 available secondary AML patient expand access protocol commercialization CPX-351 information clinical utility know . This study Phase IV multicenter , single-arm open-label Expanded Access Protocol ( EAP ) CPX-351 patient secondary acute myeloid leukemia suitable treatment intensive chemotherapy . Patients may receive two induction four consolidation course . Patients monitor safety ( early death , serious adverse event , grade 3 4 adverse event , etc . ) study SAEs 30 day last dose CPX-351 . Study enrollment available commercialization CPX-351 .</detailed_description>
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<mesh_term>Cytarabine</mesh_term>
	<mesh_term>Daunorubicin</mesh_term>
	<criteria>Ability understand voluntarily give informed consent Age 60 75 year Pathological diagnosis AML accord WHO criteria ( least 20 % blast peripheral blood bone marrow ) Confirmation : Therapy related AML : tAML must history prior cytotoxic therapy ionize radiotherapy unrelated disease AML history myelodysplasia AML history CMMoL De novo AML karyotypic abnormality characteristic MDS per WHO ( see table ) Eastern Cooperative Oncology Group ( ECOG ) performance status 02 Laboratory value fulfil follow : Serum creatinine &lt; 2.0 mg/dL Serum total bilirubin &lt; 2.0 mg/dL Serum alanine aminotransferase aspartate aminotransferase &lt; 3 time ULN Note : If elevate liver enzyme ULN related disease , high level ALT AST may consider . Cardiac ejection fraction ≥ 50 % echocardiography MUGA Except CMMoL , patient history myeloproliferative neoplasm ( MPN ) ( defined history essential thrombocytosis polycythemia vera , idiopathic myelofibrosis prior diagnosis AML ) combine MDS/MPN eligible . Acute promyelocytic leukemia [ ( 15 ; 17 ) ] favorable cytogenetics , include ( 8 ; 21 ) inv16 know time registration . Clinical evidence active CNS leukemia Patients active ( uncontrolled , metastatic ) second malignancy exclude . In event rapidly proliferative disease use hydroxyurea permit 24 hour start study treatment . Any major surgery radiation therapy within four week . Patients prior cumulative anthracycline exposure great 368 mg/mP2P daunorubicin ( equivalent ) . Any serious medical condition , laboratory abnormality psychiatric illness would prevent obtain informed consent Patients myocardial impairment cause ( e.g . cardiomyopathy , ischemic heart disease , significant valvular dysfunction , hypertensive heart disease , congestive heart failure ) result heart failure New York Heart Association Criteria ( Class III IV stag ) Active uncontrolled infection . Patients infection receive treatment ( antibiotic , antifungal antiviral treatment ) may enter study must afebrile hemodynamically stable ≥72 hr . Current evidence invasive fungal infection ( blood tissue culture ) ; patient recent fungal infection must post treatment negative culture ( ) eligible ; know HIV ( new testing require ) evidence active hepatitis B C infection ( rise transaminase value ) Hypersensitivity cytarabine , daunorubicin liposomal product History Wilson 's disease coppermetabolism disorder</criteria>
	<gender>All</gender>
	<minimum_age>60 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>VYXEOS</keyword>
</DOC>